Physician profile
Haritha Ackula
NPI 1346775293
$3,376.26
in general payments reported to CMS, 2019-2025
36 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.16 · 2022: $170 · 2023: $720 · 2024: $1,115 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.63 |
| Education | $392.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $352.71 | 2023-2025 | Jakafi, Monjuvi |
| Pfizer INC. | $278.43 | 2023-2025 | |
| Janssen Biotech, INC. | $251.44 | 2022-2025 | Erleada, Carvykti, Darzalex |
| Celgene Corporation | $236.95 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $190.62 | 2024-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $171.51 | 2022-2025 | Opdivo, Krazati, Opdualag |
| Alexion Pharmaceuticals, INC. | $161.43 | 2023-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $122.24 | 2024-2025 | |
| Astellas Pharma US INC | $121.10 | 2025 | Vyloy |
| Glaxosmithkline, LLC. | $116.57 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $104.52 | 2023-2025 | Trodelvy |
| Seagen INC. | $102.04 | 2023 | Adcetris |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Abbvie INC. | $91.36 | 2024-2025 | |
| Array Biopharma INC | $76.11 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $74.05 | 2024-2025 | Enhertu, Tagrisso |
| Deciphera Pharmaceuticals INC. | $73.57 | 2023-2025 | Qinlock, Tgct |
| Eisai INC. | $54.78 | 2024-2025 | |
| Sobi, INC | $53.89 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $53.89 | 2025 | |
| Amgen INC. | $52.58 | 2023 | Kyprolis, Blincyto, Lumakras |
| Servier Pharmaceuticals LLC | $49.87 | 2024-2025 | |
| Adc Therapeutics America, INC. | $47.27 | 2023-2024 | |
| Genzyme Corporation | $47.17 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.86 | 2023-2024 | Iclusig |
| Daiichi Sankyo INC. | $40.50 | 2024 | Enhertu |
| Beigene USA, INC. | $40.24 | 2024-2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $40.03 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Jazz Pharmaceuticals INC. | $36.57 | 2024-2025 | |
| Exelixis INC. | $35.87 | 2024-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $32.77 | 2024 | Libtayo |
| Karyopharm Therapeutics INC. | $32.26 | 2023 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $31.35 | 2025 | |
| Lilly USA, LLC | $23.28 | 2025 | Jaypirca, Verzenio |
| Tempus Ai, INC | $22.86 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $14.57 | 2023 | Imbruvica, Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haritha Ackula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.